Soleno Therapeutics Inc(SLNO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 30.09 | EPS (ttm) | 1.76 | Insider Own | 1.31% | Shs Outstand | 51.7M | Perf Week | - |
| Market Cap | 2.76B | Forward P/E | 7.15 | EPS next Y | 72.91% | Insider Trans | -2.02% | Shs Float | 51.4M | Perf Month | 0.47% |
| Enterprise Value | 2.56B | PEG | 0.04 | EPS next Q | 0.99 | Inst Own | 98.36% | Short Float | 8.56% | Perf Quarter | 39.17% |
| Income | 0.10B | P/S | 9.69 | EPS this Y | 999.36% | Inst Trans | -25.76% | Short Ratio | 1.29 | Perf Half Y | 15.47% |
| Sales | 0.29B | P/B | 5.53 | EPS next 5Y | 196.31% | ROA | 20.64% | Short Interest | 4.41M | Perf YTD | 14.49% |
| Book/sh | 9.59 | P/C | 10.81 | EPS past 3/5Y | - | ROE | 26.27% | 52W High | -41.31% ($90.32) | Perf Year | -29.39% |
| Cash/sh | 4.9 | P/FCF | 26.21 | Sales past 3/5Y | - | ROIC | 17.42% | 52W Low | 80.12% ($29.43) | Perf 3Y | 1160.64% |
| Dividend Est. | - | EV/EBITDA | 27.99 | EPS Y/Y TTM | 139.08% | Gross Margin | 98.63% | Volatility(W/M) | 0.08% 0.15% | Perf 5Y | 263.92% |
| Dividend TTM | - | EV/Sales | 8.99 | Sales Y/Y TTM | - | Oper. Margin | 31.4% | ATR (14) | 0.45 | Perf 10Y | -40.1% |
| Dividend Ex-Date | - | Quick Ratio | 5.32 | EPS Q/Q | 162.38% | Profit Margin | 33.55% | RSI (14) | 77.66 | Recom | 2.5 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.62 | Sales Q/Q | - | SMA20 | 0.29% ($52.86) | Beta | -2.23 | Target Price | $53 |
| Payout | - | Debt/Eq | 0.11 | Earnings | 2026/5/7 | SMA50 | 16.45% ($45.52) | Rel Volume | 0 | Prev Close | $53.01 |
| Employees | 182 | LT Debt/Eq | 0.11 | EPS/Sales Surpr. | -13.24% 0.87% | SMA200 | 0.85% ($52.56) | Avg Volume(3M) | 3.41M | Price | $53.01 |
| IPO | 2014/11/13 | Option/Short | Yes/No | Trades | 0 | Volume | - | Change | - |
Company
SLNO is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 A US biotech company that develops and commercializes treatments for rare diseases. It develops and commercializes therapies for rare genetic disorders and is drawing attention for progress in bringing new drugs to market and expanding prescriptions. It is a biotech company specialized in rare disease treatments.
Over the past 1 year, roughly in the middle
41% below its 1-year high.
SLNO makes money exceptionally well
31.4% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +999.4% this year.
Tap to view numbers
But it is not cheap
Trading at 30.1 times earnings.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +1160.6% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 98.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
LFSC 0.01%
LABU 0.01%
BBC 0.01%
XBI 0.01%
FMED 0.00%It ranks #4 in the industry
Based on market cap of $3B.
SLNO $3B PER 30.1
VRTX $132B PER 30.4
REGN $82B PER 19.7
MRNA $78B PER -
FAQ
What kind of company is SLNO?
SLNO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SLNO?
The market cap of SLNO is approximately $2.8B, ranking 1,858 within its sector.
What is the P/E ratio of SLNO?
SLNO has a P/E ratio of approximately 30.1x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for SLNO?
SLNO has recorded a 52-week high of $90.32 and a low of $29.43.
